Genmab Reports Q3 2025 DARZALEX Sales of $3.67 Billion
- DARZALEX Q3 2025 sales reached $3.672 billion.
- U.S. sales were $2.088 billion; international sales were $1.584 billion.
- Genmab receives royalties from Johnson & Johnson for DARZALEX sales.
Q3 2025 DARZALEX Sales
Genmab announced that the net sales of DARZALEX (daratumumab) for the third quarter of 2025 totaled USD 3.672 billion. The sales figures include both the intravenous and subcutaneous (SC) versions of the product, with the SC version known as DARZALEX FASPRO in the U.S.
Sales Breakdown
In the United States, DARZALEX sales reached USD 2.088 billion, while sales in the rest of the world amounted to USD 1.584 billion. These figures were reported by Johnson & Johnson, which holds the exclusive worldwide license to develop, manufacture, and commercialize daratumumab.
Royalty Agreement
Genmab receives royalties on the worldwide net sales of DARZALEX from Johnson & Johnson. This agreement covers both the intravenous and SC products, reflecting Genmab's ongoing collaboration with Johnson & Johnson in the commercialization of daratumumab.
Source: Genmab